Titanocene Y also known as bis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride or dichloridobis(η5-(p-methoxybenzyl)cyclopentadienyl)titanium is an organotitanium compound that has been investigated for use as an anticancer drug. [1]
Titanocene dichloride is known to be a potential anticancer drug [2] since the late 1970s. After initial clinical trials against breast and renal-cell cancer were performed with this compound, [3] [4] the search for improved derivatives started. [5] Particularly, lipophilic titanocene dichloride derivatives derived from fulvenes [6] were synthesised in structural diversity and this led to the development of bis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride, [1] which became better known in the literature under its trivial name of Titanocene Y.
Titanocene Y is a cytotoxic apoptosis-inducing [7] and anti-angiogenic [8] drug candidate targeting renal-cell cancer and other solid tumors. [9] [10] The compound is transported via serum albumin selectively into cancer cells [11] [12] and targets their DNA by coordinating strongly to phosphate groups. [13] [14] Additionally, Titanocene Y is able to induce apoptosis via the FAS receptor pathway. [15] Very encouraging is the fact that Titanocene Y is breaking platinum-resistance in human colon and human lung cancer cells, [16] which might make it attractive as a cytotoxic component of future 2nd or 3rd line cancer treatments.
Titanocene Y was tested extensively in vivo; it showed promising results against xenografted human epidermoid carcinoma [17] and prostate cancer, [18] while best results are reached against breast [19] and renal-cell cancer. [20] Titanocene Y can be given in the mouse in high dosages and it shows generally mild toxicity in the form of diarrhea. Titanocene Y is not patent protected and would therefore benefit from non-commercial sponsoring to develop it into a cytotoxic drug candidate for the treatment of advanced renal-cell cancer – an area in need of better therapies.
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
Titanocene Y also known as bis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride or dichloridobis(η5-(p-methoxybenzyl)cyclopentadienyl)titanium is an organotitanium compound that has been investigated for use as an anticancer drug. [1]
Titanocene dichloride is known to be a potential anticancer drug [2] since the late 1970s. After initial clinical trials against breast and renal-cell cancer were performed with this compound, [3] [4] the search for improved derivatives started. [5] Particularly, lipophilic titanocene dichloride derivatives derived from fulvenes [6] were synthesised in structural diversity and this led to the development of bis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride, [1] which became better known in the literature under its trivial name of Titanocene Y.
Titanocene Y is a cytotoxic apoptosis-inducing [7] and anti-angiogenic [8] drug candidate targeting renal-cell cancer and other solid tumors. [9] [10] The compound is transported via serum albumin selectively into cancer cells [11] [12] and targets their DNA by coordinating strongly to phosphate groups. [13] [14] Additionally, Titanocene Y is able to induce apoptosis via the FAS receptor pathway. [15] Very encouraging is the fact that Titanocene Y is breaking platinum-resistance in human colon and human lung cancer cells, [16] which might make it attractive as a cytotoxic component of future 2nd or 3rd line cancer treatments.
Titanocene Y was tested extensively in vivo; it showed promising results against xenografted human epidermoid carcinoma [17] and prostate cancer, [18] while best results are reached against breast [19] and renal-cell cancer. [20] Titanocene Y can be given in the mouse in high dosages and it shows generally mild toxicity in the form of diarrhea. Titanocene Y is not patent protected and would therefore benefit from non-commercial sponsoring to develop it into a cytotoxic drug candidate for the treatment of advanced renal-cell cancer – an area in need of better therapies.
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)